Elevated calcium levels in the blood—a complication of kidney cancers known as hypercalcemia—may be successfully treated with a class of medications called HIF-2α inhibitors developed by UT Southwestern Medical Center, a new study shows. The findings, published in Cancer Discovery by a team at UTSW, offer hope to patients who develop this condition.
This article was originally published on MedicalXpress.com